HRP20201561T1 - Uporaba mikrobnih zajednica za zdravlje ljudi i životinja - Google Patents
Uporaba mikrobnih zajednica za zdravlje ljudi i životinja Download PDFInfo
- Publication number
- HRP20201561T1 HRP20201561T1 HRP20201561TT HRP20201561T HRP20201561T1 HR P20201561 T1 HRP20201561 T1 HR P20201561T1 HR P20201561T T HRP20201561T T HR P20201561TT HR P20201561 T HRP20201561 T HR P20201561T HR P20201561 T1 HRP20201561 T1 HR P20201561T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- roseburia
- bacteria
- lactobacillus plantarum
- lmg
- Prior art date
Links
- 230000000813 microbial effect Effects 0.000 title 1
- 241000702462 Akkermansia muciniphila Species 0.000 claims 8
- 241001505572 Anaerostipes caccae Species 0.000 claims 8
- 241000301580 Butyricicoccus pullicaecorum Species 0.000 claims 8
- 241000605980 Faecalibacterium prausnitzii Species 0.000 claims 8
- 241001394655 Roseburia inulinivorans Species 0.000 claims 8
- 241000894006 Bacteria Species 0.000 claims 7
- 240000006024 Lactobacillus plantarum Species 0.000 claims 7
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 7
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 7
- 241000872832 Roseburia hominis Species 0.000 claims 6
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 208000010643 digestive system disease Diseases 0.000 claims 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 3
- 241000606125 Bacteroides Species 0.000 claims 2
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 claims 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims 2
- 241001608472 Bifidobacterium longum Species 0.000 claims 2
- 241000194031 Enterococcus faecium Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000394636 Lactobacillus mucosae Species 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 244000052616 bacterial pathogen Species 0.000 claims 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 230000007358 intestinal barrier function Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000027244 Dysbiosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022678 Intestinal infections Diseases 0.000 claims 1
- 241000560101 Lactobacillus plantarum ZJ316 Species 0.000 claims 1
- 241000736262 Microbiota Species 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000002389 Pouchitis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000007140 dysbiosis Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005027 intestinal barrier Anatomy 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (13)
1. Pripravak naznačen time što se sastoji uglavnom od bakterija koje pripadaju vrstama Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans, Roseburia hominis, Akkermansia muciniphila, Lactobacillus plantarum i Anaerostipes caccae, ili, koje pripadaju vrstama Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans, Akkermansia muciniphila, Lactobacillus plantarum i Anaerostipes caccae, ili, koje pripadaju vrstama Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans, Roseburia hominis, Akkermansia muciniphila, Lactobacillus plantarum, Anaerostipes caccae, Escherichia coli, Enterococcus faecium, Lactobacillus mucosae, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides thetaiotaomicron i Bacteroides vulgatum.
2. Pripravak prema patentnom zahtjevu 1, naznačen time što je za uporabu za prevenciju ili liječenje simptoma povezanih s gastrointestinalnim poremećajem.
3. Pripravak za uporabu prema patentnom zahtjevu 2 naznačen time što navedeni gastrointestinalni poremećaj predstavlja poremećaj barijerne funkcije crijeva, proljev, zatvor, sindrom iritabilnog crijeva, upalnu bolest crijeva, Crohnovu bolest, ulcerozni kolitis, celijakiju, pouchitis, mukozitis, infekciju crijeva, disbiozu crijevnih mikrobiota i bilo koju njihovu kombinaciju.
4. Pripravak za uporabu prema patentnim zahtjevima 2-3 naznačen time što se navedeni gastrointestinalni poremećaj sprječava ili liječi: a) poticanjem rasta i/ili aktivnosti jedne ili ograničenog broja korisnih bakterija u crijevnom traktu, b) inhibiranjem rasta i/ili aktivnosti jedne ili ograničenog broja patogenih bakterija u crijevnom traktu, c) relativno povećanje vezanosti nepatogenih bakterija na sluznicu gastrointestinalne površine, d) smanjenje nekontroliranog unosa antigena, proupalnih, bakterija ili bakterijskih proizvoda u crijevima, e) osiguravanje protuupalnog djelovanja na crijevnoj površini, f) povećavanje funkcioniranja crijevne barijere, g) proizvodi bakterijske metabolite ili h) bilo koju kombinaciju a) do g).
5. Pripravak koji se sastoji uglavnom od bakterija koje pripadaju vrstama Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans, Roseburia hominis, Akkermansia muciniphila, Lactobacillus plantarum i Anaerostipes caccae, ili, koje pripadaju vrstama Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans, Akkermansia muciniphila, Lactobacillus plantarum i Anaerostipes caccae, ili, koje pripadaju vrstama Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans, Roseburia hominis, Akkermansia muciniphila, Lactobacillus plantarum, Anaerostipes caccae, Escherichia coli, Enterococcus faecium, Lactobacillus mucosae, Bifidobacterium adolescentis, Bifidobacterium longum, Bacteroides thetaiotaomicron, Bacteroides vulgatum i sadrži jedan ili više prebiotika.
6. Pripravak prema patentnim zahtjevima 1- 2 i 5, naznačen time što se navedene bakterije uzgajaju zajedno u fermentoru prije davanja navedenog pripravka kako bi se spriječili ili liječili navedeni gastrointestinalni poremećaji.
7. Pripravak prema patentnom zahtjevu 6 naznačen time što je navedeni fermentor dinamički simulator gastrointestinalnog trakta.
8. Pripravak prema patentnom zahtjevu 1 naznačen time što su navedene bakterije odabrane s popisa sljedećih sojeva: Faecalibacterium prausnitzii LMG P-29362, Faecalibacterium prausnitzii DSMZ 17677, Butyricicoccus pullicaecorum LMG P-29360, Butyricicoccus pullicaecorum LMG24109, Roseburia inulinivorans LMG P-29365, Roseburia inulinivorans DSMZ 16841, Roseburia hominis LMG P-29364, Roseburia hominis DSMZ 16839, Akkermansia muciniphila LMG P-29361, Akkermansia muciniphila DSMZ 22959, Lactobacillus plantarum LMG P-29366, Lactobacillus plantarum ZJ316, Anaerostipes caccae LMG P-29359, Anaerostipes caccae DSMZ 14662 ili sojeva koji pokazuju najmanje 97% identičnosti sekvence sa sekvencama 16SrRNA barem jednog od navedenih sojeva.
9. Pripravak prema patentnim zahtjevima 1- 2 i 5 do 8, naznačen time što je navedeni pripravak farmaceutski pripravak koji je formuliran bilo kao oblik za rektalnu primjenu ili oblik za oralno gutanje.
10. Pripravak prema patentnom zahtjevu 9 naznačen time što je navedeni oblik za oralno gutanje kapsula, mikrokapsula, tableta, granula, prah, pastila, pilula, suspenzija ili sirup.
11. Pripravak prema patentnom zahtjevu 10 naznačen time što je ugrađen u hranu, piće, dodatak hrani ili nutraceutik.
12. Pripravak prema patentnim zahtjevima 1-2 i 5-11 naznačen time što navedeni pripravak sadrži između 105 i 1011 jedinica bakterija koje tvore koloniju.
13. Reaktor naznačen time što sadrži pripravak kako je definiran u bilo kojem od zahtjeva 1 do i 5-12
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016154288 | 2016-02-04 | ||
| PCT/EP2017/052422 WO2017134240A1 (en) | 2016-02-04 | 2017-02-03 | Use of microbial communities for human and animal health |
| EP17703726.4A EP3411052B8 (en) | 2016-02-04 | 2017-02-03 | Use of microbial communities for human and animal health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201561T1 true HRP20201561T1 (hr) | 2021-01-22 |
Family
ID=74183565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201561TT HRP20201561T1 (hr) | 2016-02-04 | 2020-09-30 | Uporaba mikrobnih zajednica za zdravlje ljudi i životinja |
Country Status (2)
| Country | Link |
|---|---|
| HR (1) | HRP20201561T1 (hr) |
| PT (1) | PT3411052T (hr) |
-
2017
- 2017-02-03 PT PT177037264T patent/PT3411052T/pt unknown
-
2020
- 2020-09-30 HR HRP20201561TT patent/HRP20201561T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3411052T (pt) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2969690T3 (es) | Lactobacillus casei o Lactobacillus paracasei para su uso en el tratamiento de infecciones por Clostridium difficile | |
| RU2018131244A (ru) | Использование микробных сообществ для лечения человека и животных | |
| EP3341001B1 (en) | Composition and method for treatment and prophylaxis of intestinal infection and inflammation | |
| Salminen et al. | Interaction of probiotics and pathogens—benefits to human health? | |
| Nami et al. | Assessment of probiotic potential and anticancer activity of newly isolated vaginal bacterium Lactobacillus plantarum 5BL | |
| ES2641289T3 (es) | Cepas bacterianas probióticas y composición simbiótica que las contiene destinada a alimento para lactantes | |
| JP2019508486A5 (hr) | ||
| Bayoumi et al. | In vitro inhibition of expression of virulence genes responsible for colonization and systemic spread of enteric pathogens using Bifidobacterium bifidum secreted molecules | |
| Chingwaru et al. | Potential of Zimbabwean commercial probiotic products and strains of Lactobacillus plantarum as prophylaxis and therapy against diarrhoea caused by Escherichia coli in children | |
| WO2016205394A1 (en) | Multistrain probiotic blends for treatment of gastrointestinal conditions and improving or maintaining gastrointestinal health | |
| Balgir et al. | In vitro and in vivo survival and colonic adhesion of Pediococcus acidilactici MTCC5101 in human gut | |
| Yoda et al. | Oral administration of Lactobacillus gasseri TMC0356 stimulates peritoneal macrophages and attenuates general symptoms caused by enteropathogenic Escherichia coli infection | |
| CN114040770A (zh) | 用于治疗、缓和或预防痤疮的组合物 | |
| Maurya et al. | Probiotics: an approach towards health and disease | |
| KR20180031247A (ko) | 유산균 함유 건강보조식품 | |
| HRP20201561T1 (hr) | Uporaba mikrobnih zajednica za zdravlje ljudi i životinja | |
| Moorthy et al. | Lactobacilli inhibit Shigella dysenteriae 1 induced pro-inflammatory response and cytotoxicity in host cells via impediment of Shigella–host interactions | |
| CA3153729A1 (en) | Spore-based probiotic composition for modulation of microbiome in humans | |
| Pishva et al. | Antibacterial effect of authochlorous Lactobacillus strains isolated from traditional yogurts | |
| Jang et al. | Adhesion activity of Lactobacillus plantarum PM 008 isolated from kimchi on the intestine of mice | |
| Fatima et al. | safety and protective effect of bifidobactérium spp. Used as probiotic agent in vivo against enteropathogenic escherichia coli | |
| Combrinck et al. | Probiotics and Prebiotics | |
| Wang | Comparison of Microbial Quality of Commercial Probiotic Dietary Supplements | |
| Verma et al. | Beneficence of probiotics and prebiotics for human health: a review. | |
| Gaikwad et al. | PROBIOTICS AND ITS EFFECTS ON GASTROINTESTINAL INFECTIONS: AN OVERVIEW |